GPT-Rosalind (OpenAI) vs Nano Banana 2.1 (Gemini Nano Banana 2.1, formerly Nano Banana 2)

Nano Banana 2.1 (Gemini Nano Banana 2.1, formerly Nano Banana 2) is the clear winner: 8.9/10 (A-tier) versus 6.8/10 (C-tier). GPT-Rosalind (OpenAI) isn't a bad tool, but on every category that drives the overall score, Nano Banana 2.1 (Gemini Nano Banana 2.1, formerly Nano Banana 2) comes out ahead. The tier gap is repeatable -- not methodology noise -- and the day-to-day experience reflects it.

On pricing, Nano Banana 2.1 (Gemini Nano Banana 2.1, formerly Nano Banana 2) starts free while GPT-Rosalind (OpenAI) requires a paid plan from day one ($0+). If you're testing the waters or running an occasional workload, that gap matters more than the score differential. GPT-Rosalind (OpenAI) starts at $0; Nano Banana 2.1 (Gemini Nano Banana 2.1, formerly Nano Banana 2) starts at $0. Compare what each entry tier actually unlocks before you compare list prices -- the limits matter more than the headline number.

By use case: pick GPT-Rosalind (OpenAI) when researchers and enterprises in biology, drug discovery, protein science, translational medicine, or adjacent life-sciences domains who can get trusted access. Pick Nano Banana 2.1 (Gemini Nano Banana 2.1, formerly Nano Banana 2) when designers, marketers, and content creators who need readable text in images (social posts, ad creative, book covers, infographics, event flyers) and who are already using or willing to pay for gemini. The two tools aren't fighting for the same person -- they're aiming at adjacent jobs that occasionally overlap. If you're squarely in Nano Banana 2.1 (Gemini Nano Banana 2.1, formerly Nano Banana 2)'s lane, the tier-list ranking and the use-case fit point the same direction; if you're in GPT-Rosalind (OpenAI)'s lane, the score gap matters less than the fit.

Bottom line: Nano Banana 2.1 (Gemini Nano Banana 2.1, formerly Nano Banana 2) is the better tool for most people right now. Pick GPT-Rosalind (OpenAI) only when researchers and enterprises in biology, drug discovery, protein science, translational medicine, or adjacent life-sciences domains who can get trusted access -- that's its lane, and inside that lane it still earns its place.